Articles

UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
ustekinumab (1033) 1033
humans (969) 969
science & technology (960) 960
life sciences & biomedicine (955) 955
psoriasis (698) 698
dermatology (584) 584
psoriasis - drug therapy (546) 546
female (463) 463
male (460) 460
ustekinumab - therapeutic use (401) 401
middle aged (373) 373
adult (369) 369
treatment outcome (328) 328
antibodies, monoclonal - therapeutic use (292) 292
dermatologic agents - therapeutic use (292) 292
severity of illness index (225) 225
antibodies, monoclonal, humanized - therapeutic use (223) 223
adalimumab (222) 222
infliximab (200) 200
antibodies, monoclonal, humanized (180) 180
etanercept (172) 172
aged (154) 154
care and treatment (138) 138
tumor necrosis factor-alpha - antagonists & inhibitors (136) 136
drug therapy (133) 133
biological and medical sciences (120) 120
monoclonal antibodies (120) 120
biological products - therapeutic use (117) 117
dermatologic agents - adverse effects (117) 117
gastroenterology & hepatology (117) 117
medical sciences (116) 116
crohn's disease (115) 115
psoriatic arthritis (110) 110
biologics (109) 109
crohn disease - drug therapy (108) 108
pharmacology & pharmacy (106) 106
retrospective studies (105) 105
ustekinumab - adverse effects (105) 105
adalimumab - therapeutic use (103) 103
arthritis, psoriatic - drug therapy (103) 103
antibodies, monoclonal - adverse effects (100) 100
cytokines (98) 98
dermatologic agents (92) 92
inflammatory bowel disease (92) 92
arthritis (91) 91
clinical trials (88) 88
formulae, receipts, prescriptions (88) 88
patients (86) 86
analysis (82) 82
abridged index medicus (79) 79
crohn’s disease (79) 79
interleukin-23 - antagonists & inhibitors (79) 79
animals (76) 76
secukinumab (76) 76
antibodies, monoclonal, humanized - adverse effects (75) 75
medicine & public health (75) 75
rheumatology (75) 75
etanercept - therapeutic use (74) 74
infliximab - therapeutic use (74) 74
quality of life (74) 74
interleukin-12 - antagonists & inhibitors (70) 70
psoriasis. parapsoriasis. lichen (70) 70
young adult (70) 70
dermatologic agents - administration & dosage (68) 68
ustekinumab - administration & dosage (68) 68
adolescent (66) 66
methotrexate (66) 66
psoriasis - immunology (65) 65
immunology (64) 64
immunosuppressive agents - therapeutic use (64) 64
antirheumatic agents - therapeutic use (63) 63
anti-inflammatory agents - therapeutic use (62) 62
immunoglobulin g - therapeutic use (61) 61
psoriasis - complications (60) 60
antibodies, monoclonal - administration & dosage (59) 59
interleukins (59) 59
double-blind method (58) 58
methotrexate - therapeutic use (58) 58
psoriasis - pathology (58) 58
interleukin-23 - immunology (57) 57
drug administration schedule (56) 56
biological products (55) 55
biological therapy (55) 55
health aspects (55) 55
il-23 (54) 54
immunologic factors - therapeutic use (54) 54
general & internal medicine (53) 53
randomized controlled trials as topic (53) 53
follow-up studies (51) 51
medicine, general & internal (51) 51
dose-response relationship, drug (50) 50
internal medicine (47) 47
interleukin 12 (46) 46
receptors, tumor necrosis factor - therapeutic use (46) 46
tumor necrosis factor-tnf (46) 46
antibodies, monoclonal, humanized - administration & dosage (45) 45
psoriasis - diagnosis (45) 45
drug therapy, combination (44) 44
interleukin-12 - immunology (43) 43
ulcerative colitis (43) 43
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1298) 1298
Korean (48) 48
Spanish (26) 26
French (23) 23
German (17) 17
Russian (17) 17
Polish (10) 10
Czech (5) 5
Japanese (5) 5
Chinese (4) 4
Portuguese (3) 3
Dutch (2) 2
Croatian (1) 1
Finnish (1) 1
Hebrew (1) 1
Hungarian (1) 1
Italian (1) 1
Slovak (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Ustekinumab as Induction and Maintenance Therapy for Crohn’s Disease
by Feagan, Brian G and Sandborn, William J and Gasink, Christopher and Jacobstein, Douglas and Lang, Yinghua and Friedman, Joshua R and Blank, Marion A and Johanns, Jewel and Gao, Long-Long and Miao, Ye and Adedokun, Omoniyi J and Sands, Bruce E and Hanauer, Stephen B and Vermeire, Severine and Targan, Stephan and Ghosh, Subrata and de Villiers, Willem J and Colombel, Jean-Frédéric and Tulassay, Zsolt and Seidler, Ursula and Salzberg, Bruce A and Desreumaux, Pierre and Lee, Scott D and Loftus, Edward V and Dieleman, Levinus A and Katz, Seymour and Rutgeerts, Paul and UNITI-IM-UNITI Study Grp and UNITI–IM-UNITI Study Group
The New England journal of medicine, ISSN 0028-4793, 11/2016, Volume 375, Issue 20, pp. 1946 - 1960
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Humans | Middle Aged | Induction Chemotherapy | Male | Remission Induction | Ustekinumab - therapeutic use | Ustekinumab - adverse effects | Ustekinumab - pharmacokinetics | Crohn Disease - drug therapy | Ustekinumab - immunology | Adult | Female | Maintenance Chemotherapy | Infusions, Intravenous | Intravenous administration | Cytokines | Body weight | Clinical trials | Interleukin 23 | Interleukin 12 | Antagonists | Patients | Crohns disease | Side effects | Tumor necrosis factor | Immunotherapy | Monoclonal antibodies | Tumor necrosis factor-TNF | Remission | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text A randomised phase II study evaluating the efficacy and safety of subcutaneously administered ustekinumab and guselkumab in patients with active rheumatoid arthritis despite treatment with methotrexate
by Smolen, Josef S and Agarwal, Sandeep K and Ilivanova, Elena and Xu, Xie Lillian and Miao, Ye and Zhuang, Yanli and Nnane, Ivo and Radziszewski, Waldemar and Greenspan, Andrew and Beutler, Anna and Baker, Daniel
Annals of the rheumatic diseases, ISSN 0003-4967, 05/2017, Volume 76, Issue 5, pp. 831 - 839
Life Sciences & Biomedicine | Rheumatology | Science & Technology | Severity of Illness Index | Double-Blind Method | Antirheumatic Agents - administration & dosage | Humans | Middle Aged | Antirheumatic Agents - immunology | Antibodies, Monoclonal - pharmacokinetics | Antibodies, Monoclonal - therapeutic use | Male | Methotrexate - therapeutic use | Ustekinumab - therapeutic use | Retreatment | Ustekinumab - pharmacokinetics | Antibodies, Monoclonal - administration & dosage | Arthritis, Rheumatoid - drug therapy | Treatment Failure | Ustekinumab - immunology | Adult | Antirheumatic Agents - pharmacokinetics | Female | Aged | Ustekinumab - administration & dosage | Antibodies, Monoclonal - immunology | Antirheumatic Agents - therapeutic use | Treatment outcome | Care and treatment | Rheumatoid arthritis | Analysis | Dosage and administration | Research | Methotrexate | Index Medicus | Disease Activity | Clinical and Epidemiological Research | Treatment | Rheumatoid Arthritis | 1506
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Ustekinumab for the Treatment of Refractory Crohn's Disease: The Spanish Experience in a Large Multicentre Open-label Cohort
by Khorrami, Sam and Ginard, Daniel and Marín-Jiménez, Ignacio and Chaparro, María and Sierra, Mónica and Aguas, Mariam and Sicilia, Beatriz and García-Sánchez, Valle and Suarez, Cristina and Villoria, Albert and Taxonera, Carlos and Velasco-Guardado, Antonio and Martínez-González, Javier and Gisbert, Javier P and USTEK Study Grp
Inflammatory bowel diseases, ISSN 1078-0998, 06/2016, Volume 22, Issue 7, pp. 1662 - 1669
refractory | Crohn's disease | ustekinumab | IL-12 | IL-23 | inflammatory bowel disease | Gastroenterology & Hepatology | Life Sciences & Biomedicine | Science & Technology | Drug Administration Schedule | Follow-Up Studies | Rectal Fistula - etiology | Humans | Middle Aged | Male | Ustekinumab - therapeutic use | Ustekinumab - adverse effects | Crohn Disease - complications | Spain | Cutaneous Fistula - drug therapy | Cutaneous Fistula - etiology | Retreatment | Anti-Inflammatory Agents - adverse effects | Crohn Disease - drug therapy | Injections, Subcutaneous | Rectal Fistula - drug therapy | Anti-Inflammatory Agents - therapeutic use | Adult | Anti-Inflammatory Agents - administration & dosage | Female | Retrospective Studies | Ustekinumab - administration & dosage | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis
by Sands, Bruce E and Sandborn, William J and Panaccione, Remo and O’Brien, Christopher D and Zhang, Hongyan and Johanns, Jewel and Adedokun, Omoniyi J and Li, Katherine and Peyrin-Biroulet, Laurent and Van Assche, Gert and Danese, Silvio and Targan, Stephan and Abreu, Maria T and Hisamatsu, Tadakazu and Szapary, Philippe and Marano, Colleen and UNIFI Study Grp and UNIFI Study Group
The New England journal of medicine, ISSN 0028-4793, 09/2019, Volume 381, Issue 13, pp. 1201 - 1214
ACTIVITY INDEXES | INFECTIONS | EFFICACY | INFLIXIMAB | Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Double-Blind Method | Humans | Induction Chemotherapy | Male | Ustekinumab - therapeutic use | Ustekinumab - adverse effects | Dose-Response Relationship, Drug | Patient Acuity | Anti-Inflammatory Agents - adverse effects | Injections, Subcutaneous | Anti-Inflammatory Agents - therapeutic use | Adult | Anti-Inflammatory Agents - administration & dosage | Female | Remission Induction - methods | Maintenance Chemotherapy | Colitis, Ulcerative - drug therapy | Infusions, Intravenous | Ustekinumab - administration & dosage | Treatment outcome | Drug therapy | Analysis | Ulcerative colitis | Intravenous administration | Cytokines | Research & development--R&D | Body weight | Interleukin 23 | Interleukin 12 | Hemorrhage | Testicular cancer | Esophagus | Inflammatory bowel disease | Respiratory distress syndrome | Gastroenterology | Rectum | Tumor necrosis factor-TNF | Remission | Colon | Endoscopy | Prostate cancer | Cancer | Index Medicus | Abridged Index Medicus | Life Sciences
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials
by Gordon, Kenneth B and Strober, Bruce and Lebwohl, Mark and Augustin, Matthias and Blauvelt, Andrew and Poulin, Yves and Papp, Kim A and Sofen, Howard and Puig, Lluís and Foley, Peter and Ohtsuki, Mamitaro and Flack, Mary and Geng, Ziqian and Gu, Yihua and Valdes, Joaquin M and Thompson, Elizabeth H Z and Bachelez, Hervé
The Lancet (British edition), ISSN 0140-6736, 08/2018, Volume 392, Issue 10148, pp. 650 - 661
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Tumor Necrosis Factor-alpha - metabolism | Dermatologic Agents - administration & dosage | Humans | Middle Aged | Ustekinumab - pharmacology | Antibodies, Monoclonal - adverse effects | Male | Dermatologic Agents - adverse effects | Interleukin-23 Subunit p19 - metabolism | Injections, Subcutaneous - methods | Placebos | Adult | Female | Interleukin-23 Subunit p19 - drug effects | Ustekinumab - administration & dosage | Dermatologic Agents - pharmacology | Severity of Illness Index | Psoriasis - drug therapy | Double-Blind Method | Antibodies, Monoclonal - pharmacology | Immunoglobulin G - therapeutic use | Treatment Outcome | Interleukin-12 - metabolism | Psoriasis - ethnology | Ustekinumab - adverse effects | Antibodies, Monoclonal - administration & dosage | Clinical trials | Analysis | Interleukin | Immunoglobulin G | Interleukin 23 | Infections | Evidence-based medicine | Skin cancer | Randomization | Motivation | Gangrene | Tumor necrosis factor-TNF | Safety | Active control | Effectiveness | Psoriasis | Cytokines | Adjustment | Melanoma | Patients | Weight | Quality of life | Studies | Tuberculosis | Tumor necrosis factor | Monoclonal antibodies | TNF inhibitors | Tumors | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Interleukin 23-Helper T Cell 17 axis as a treatment target for Pityriasis Rubra Pilaris
by Feldmeyer, Laurence and Mylonas, Alessio and Demaria, Olivier and Mennella, Anna and Yawalkar, Nikhil and Laffitte, Emmanuel and Hohl, Daniel and Gilliet, Michel and Conrad, Curdin
JAMA dermatology (Chicago, Ill.), ISSN 2168-6068, 04/2017, Volume 153, Issue 4, pp. 304 - 308
Life Sciences & Biomedicine | Dermatology | Science & Technology | Up-Regulation | Follow-Up Studies | Humans | Ustekinumab - pharmacology | Male | Treatment Outcome | Dermatologic Agents - therapeutic use | RNA, Messenger - metabolism | Ustekinumab - therapeutic use | Interleukin-23 - genetics | Pityriasis Rubra Pilaris - genetics | Psoriasis - pathology | Th17 Cells - metabolism | Time Factors | Biopsy | Pityriasis Rubra Pilaris - drug therapy | Adult | Cytokines - genetics | Pityriasis Rubra Pilaris - pathology | Dermatologic Agents - pharmacology
Journal Article
Details down arrow
7. Full Text Ustekinumab for Behçet's disease
by Mirouse, Adrien, M.D and Barete, Stéphane, M.D. Ph.D and Monfort, Jean-Benoît, M.D and Resche-Rigon, Matthieu, M.D., Ph.D and Bouyer, Anne-Sophie, M.D and Comarmond, Cloé, M.D. Ph.D and Sène, Damien, M.D. Ph.D and Domont, Fanny, M.D and Ferfar, Yasmina, M.D and Cacoub, Patrice, M.D. Ph.D and Saadoun, David, M.D. Ph.D
Journal of autoimmunity, ISSN 0896-8411, 2017, Volume 82, pp. 41 - 46
Allergy and Immunology | Ustekinumab | Vasculitis | Oral ulcer | Biotherapy | Behçet disease | Life Sciences & Biomedicine | Immunology | Science & Technology | Prospective Studies | Follow-Up Studies | Humans | Symptom Assessment | Behcet Syndrome - drug therapy | Male | Treatment Outcome | Ustekinumab - therapeutic use | Ustekinumab - adverse effects | Oral Ulcer - drug therapy | Biomarkers | Adult | Female | Behcet Syndrome - diagnosis | Disease Management | Behcet Syndrome - metabolism | Ustekinumab - administration & dosage | Behcet Syndrome - immunology | Medicine, Experimental | Medical research | Antiulcer drugs | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Association Between Ustekinumab Trough Concentrations and Clinical, Biomarker, and Endoscopic Outcomes in Patients With Crohn’s Disease
by Battat, Robert and Kopylov, Uri and Bessissow, Talat and Bitton, Alain and Cohen, Albert and Jain, Anjali and Martel, Myriam and Seidman, Ernest and Afif, Waqqas
Clinical gastroenterology and hepatology, ISSN 1542-3565, 09/2017, Volume 15, Issue 9, pp. 1427 - 1434.e2
Inflammatory Bowel Disease | Therapeutic Drug Monitoring | Biologic | UNITI | Gastroenterology & Hepatology | Life Sciences & Biomedicine | Science & Technology | Prospective Studies | Humans | Middle Aged | Ustekinumab - pharmacology | Child, Preschool | Male | Young Adult | Immunologic Factors - pharmacokinetics | Colonoscopy | Injections, Subcutaneous | Aged, 80 and over | Adult | Female | Ustekinumab - administration & dosage | Child | Cross-Sectional Studies | Biomarkers - analysis | Immunologic Factors - administration & dosage | Treatment Outcome | Ustekinumab - pharmacokinetics | Crohn Disease - pathology | Crohn Disease - drug therapy | Adolescent | Aged | Longitudinal Studies | Immunologic Factors - pharmacology | Viral antibodies | Antibodies | Medical colleges | Biological products | Interleukins | Care and treatment | C-reactive protein | Gastrointestinal diseases | Patient outcomes | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Maintenance of Clinical Efficacy and Radiographic Benefit Through Two Years of Ustekinumab Therapy in Patients With Active Psoriatic Arthritis: Results From a Randomized, Placebo‐Controlled Phase III Trial
by Kavanaugh, Arthur and Puig, Lluís and Gottlieb, Alice B and Ritchlin, Christopher and Li, Shu and Wang, Yuhua and Mendelsohn, Alan M and Song, Michael and Zhu, Yaowei and Rahman, Proton and McInnes, Iain B and Psummit 1 Study Grp and PSUMMIT 1 Study Group
Arthritis care & research (2010), ISSN 2151-464X, 12/2015, Volume 67, Issue 12, pp. 1739 - 1749
Life Sciences & Biomedicine | Rheumatology | Science & Technology | Disability Evaluation | Severity of Illness Index | Double-Blind Method | Joints - drug effects | Europe | Humans | Inflammation Mediators - blood | Treatment Outcome | Biomarkers - blood | North America | Remission Induction | Ustekinumab - therapeutic use | Ustekinumab - adverse effects | Cross-Over Studies | C-Reactive Protein - metabolism | Time Factors | Ustekinumab - pharmacokinetics | Arthritis, Psoriatic - blood | Arthrography | Arthritis, Psoriatic - diagnostic imaging | Arthritis, Psoriatic - drug therapy | Index Medicus | Psoriatic Arthritis
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights